Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Influenza causes substantial morbidity, particularly among older individuals. Updated data on the effectiveness of currently licensed vaccines in this population are needed.
Methods: At Kaiser Permanente Southern California, we conducted a retrospective cohort study to evaluate comparative vaccine effectiveness (cVE) of high-dose (HD), adjuvanted, and standard-dose (SD) cell-based influenza vaccines, relative to the SD egg-based vaccine. We included adults aged ≥65 years who received an influenza vaccine between 1 August 2022 and 31 December 2022, with follow-up up to 20 May 2023. Primary outcomes were: (1) influenza-related medical encounters and (2) polymerase chain reaction (PCR)-confirmed influenza-related hospitalization. Adjusted hazard ratios (aHR) were estimated by Cox proportional hazards regression, adjusting for confounders using inverse probability of treatment weighting (IPTW). cVE (%) was calculated as (1-aHR) × 100 when aHR ≤1, and ([1/aHR]-1) × 100 when aHR >1.
Results: Our study population (n = 495 119) was 54.9% female, 46.3% non-Hispanic White, with a median age of 73 years (interquartile range [IQR] 69-79). Characteristics of all groups were well balanced after IPTW. Adjusted cVEs against influenza-related medical encounters in the HD, adjuvanted, and SD cell-based vaccine groups were 9.1% (95% confidence interval [CI]: .9, 16.7), 16.9% (95% CI: 1.7, 29.8), and -6.3 (95% CI: -18.3, 6.9), respectively. Adjusted cVEs against PCR-confirmed hospitalization in the HD, adjuvanted, and SD cell-based groups were 25.1% (95% CI: .2, 43.8), 61.6% (95% CI: 18.1, 82.0), and 26.4% (95% CI: -18.3, 55.7), respectively.
Conclusions: Compared to the SD egg-based vaccine, HD and adjuvanted vaccines conferred additional protection against influenza-related outcomes in the 2022-2023 season in adults ≥65 years. Our results provide real-world evidence of the comparative effectiveness of currently licensed vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581696 | PMC |
| http://dx.doi.org/10.1093/cid/ciae375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Consensus to Conquer Challenges in Influenza Immunization in Pulmonology Practice in India: Proceedings of the Congregation on Influenza Vaccination in Chronic Lung Diseases (CIRCLE) Expert Committee Meet.
Cureus
July 2025
Infectious Disease, Zydus Lifesciences, Ahmedabad, IND.
Influenza remains a major health concern, especially for patients with chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Despite clear evidence of its benefits, annual influenza vaccination rates in India remain critically low, particularly among high-risk populations and healthcare professionals (HCPs). Key barriers include misinformation, lack of provider recommendation, and absence of structured vaccination programs.
View Article and Find Full Text PDFHigh-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial.
Circ Heart Fail
August 2025
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Department of Cardiology, Copenhagen University Ho
Influenza contributes substantially to disease burden in individuals with heart failure (HF) and is an established trigger of cardiovascular (CV) and HF events. Standard-dose inactivated influenza vaccine (SD-IIV) is recommended for HF, though immune responses may be attenuated. High-dose IIV (HD-IIV) was developed to enhance immunogenicity, but its effectiveness compared with SD-IIV against hospitalization for influenza and CV disease by HF status remains uncertain.
View Article and Find Full Text PDFInfluenza Vaccination Coverage and Predictors of Vaccination Intent Among Patients Undergoing Hemodialysis in Klang Valley, Malaysia: A Cross-Sectional Study.
Cureus
July 2025
Department of Medicine, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang, MYS.
Introduction Influenza poses a significant risk to patients receiving hemodialysis, while vaccination reduces the risk of hospitalization, cardiovascular events, and mortality. However, the influenza vaccine uptake rate is low in low- and middle-income countries. This study aimed to assess influenza vaccination coverage, knowledge, and intentions regarding influenza vaccination, as well as to identify sociodemographic and clinical factors associated with vaccination intention among patients undergoing hemodialysis in the Klang Valley, Malaysia.
View Article and Find Full Text PDFRelative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trial.
J Infect Dis
August 2025
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
Background: Frailty is a risk factor for adverse influenza-related outcomes. We assessed the effectiveness of high-dose (HD-IIV) versus standard-dose (SD-IIV) influenza vaccination according to frailty score (FS).
Methods: This was a post-hoc analysis of the randomized feasibility trial of HD-IIV versus SD-IIV conducted during the 2021-2022 influenza season in older adults aged 65-79 years.
Global association between air pollution and risk of influenza-related outcomes: a systematic review and meta-analysis.
Int J Environ Health Res
August 2025
School of Public Health, Guangzhou Medical University, Guangzhou, China.
Despite extensive research, air pollution-influenza associations remain inconsistent. This evidence synthesis aggregated evidence from 28 studies to quantify air pollution-influenza associations, employing the Office of Health Assessment and Translation (OHAT) and Navigation Guide tools for quality assessment. We derived combined relative risk () per 10 µg/m increase in air pollution, 95% confidence intervals (s) and 95% prediction intervals (s) to quantify the link.
View Article and Find Full Text PDF